MODULE 1: Optimizing the Management of ER-Positive Localized Breast Cancer — Dr Goetz

• Optimal selection and duration of adjuvant therapy for premenopausal and postmenopausal patients with ER-positive, HER2-negative localized breast cancer; clinicopathologic factors affecting the decision to consult a genomic classifier
• Major clinical findings from the Phase III RxPONDER trial evaluating the role of chemotherapy with endocrine therapy versus endocrine therapy alone for premenopausal and postmenopausal women with HR-positive, HER2-negative localized breast cancer with 1 to 3 positive lymph nodes and a 21-gene Recurrence Score^® of ≤25
• Other recent data sets informing the use of genomic assays to guide neoadjuvant and adjuvant treatment decision-making
• Key efficacy and safety outcomes observed in the Phase III monarchE trial with the addition of abemaciclib to standard adjuvant hormonal therapy for patients with HR-positive, HER2-negative localized breast cancer at high risk for recurrence
• FDA approval of adjuvant abemaciclib with endocrine therapy and identification of appropriate patients for this strategy
• Other ongoing studies (eg, NATALEE, eMonarcHER) evaluating CDK4/6 inhibitors for localized ER-positive breast cancer

MODULE 2: New and Novel Treatment Strategies for Localized Triple-Negative Breast Cancer (TNBC) — Dr Hamilton

• Clinical and biologic rationale for the investigation of PARP inhibition and immune checkpoint blockade in localized breast cancer
• Available data from the Phase III KEYNOTE-522 study of neoadjuvant pembrolizumab combined with chemotherapy and continued as a single agent after surgery for high-risk localized TNBC
• FDA approval of (neo)adjuvant pembrolizumab; patient selection and practical implementation
• Recent data on the ability of 27-gene analysis to predict response to checkpoint inhibitor therapy in localized and metastatic TNBC
• Design, eligibility criteria and key efficacy and safety findings from the Phase III OlympiA trial assessing adjuvant olaparib for patients with germline BRCA1/2 mutations and high-risk, HER2-negative breast cancer
• Recent FDA approval of adjuvant olaparib; implications for genetic testing and patient selection for this strategy
• Other novel agents and strategies under investigation for localized TNBC

MODULE 3: Considerations in the Care of Patients with Localized HER2-Positive Breast Cancer — Dr Krop

• Clinical factors affecting the decision to administer neoadjuvant systemic treatment to patients with HER2-positive localized breast cancer; selecting a neoadjuvant regimen
• Available data (eg, ADAPT HR+/HER2-, TRAIN-2) exploring the feasibility of chemotherapy de-escalation in the setting of dual HER2 blockade for patients with localized disease
• Key data supporting the use of adjuvant T-DM1 for HER2-positive breast cancer; current nonresearch role, if any, for patients beyond those with residual disease after neoadjuvant therapy
• Patient selection for and clinical factors guiding the use of neratinib as extended-adjuvant therapy; improvement in rates of CNS recurrence observed after long-term follow-up of the Phase III ExteNET study
• Dose escalation and other available strategies to reduce the toxicities associated with postadjuvant neratinib
• Ongoing clinical trials (eg, DESTINY-Breast05, CompassHER2 RD) investigating novel HER2-targeted strategies for HER2-positive localized breast cancer

MODULE 4: Evolving Clinical Decision-Making for Patients with HER2-Positive Metastatic Breast Cancer (mBC) — Dr Cortés

• Clinical factors in the selection and sequencing of therapy for patients with HER2-positive mBC; role of rechallenge with anti-HER2 therapies received in the (neo)adjuvant setting
• Published data from the pivotal HER2CLIMB, DESTINY-Breast01 and NALA studies of tucatinib/trastuzumab/capecitabine, trastuzumab deruxtecan (T-DXd) and neratinib/capecitabine, respectively, for HER2-positive mBC
• Key efficacy and safety findings from the Phase III DESTINY-Breast03 trial evaluating T-DXd versus T-DM1 for patients with HER2-positive mBC previously treated with trastuzumab and a taxane; recent FDA approval of T-DXd in this setting
• Antitumor activity of tucatinib/trastuzumab/capecitabine, T-DXd and neratinib/capecitabine among patients with brain metastases
• Outcomes observed with the use of T-DXd in patients with HER2-low mBC in the Phase III DESTINY-Breast04 study; implications for routine practice
• Ongoing clinical research evaluating novel HER2-targeted strategies for HER2-positive mBC

MODULE 5: Selection and Sequencing of Therapy for ER-Positive, HER2-Negative mBC — Dr Rugo

• Long-term follow-up data, including overall survival findings, with CDK4/6 inhibitors for patients with ER-positive mBC; factors in the selection of a CDK4/6 inhibitor and an endocrine partner for first-line treatment
• Proposed mechanisms of resistance to CDK4/6 inhibition; ongoing clinical trials (eg, MAINTAIN, PACE, PALMIRA) assessing CDK4/6 inhibitor re-treatment after disease progression on prior CDK4/6 inhibitor therapy
• Published research findings with alpelisib/fulvestrant in patients with ER-positive mBC and PIK3CA mutations; optimal incorporation into current management algorithms
• Published data with and ongoing investigation of oral SERDs (eg, elacestrant, amcenestrant, giredestrant, imlunestrant, camizestrant) for patients with ER-positive, HER2-negative mBC
• Key findings from the Phase III TROPiCS-02 trial evaluating sacituzumab govitecan for HR-positive, HER2-negative mBC
• Other novel agents and strategies under investigation for ER-positive mBC (eg, capivasertib, patritumab deruxtecan, datopotamab deruxtecan)

MODULE 6: Recent Advances in the Care of Patients with Metastatic TNBC (mTNBC) — Dr Tolaney

• Long-term efficacy and safety findings from the Phase III KEYNOTE-355 study of pembrolizumab/chemotherapy for previously untreated PD-L1-positive mTNBC
• Key clinical research findings guiding the optimal use of PARP inhibitors for mTNBC
• Final results from the Phase III ASCENT trial comparing sacituzumab govitecan to physician’s choice of chemotherapy for relapsed/refractory mTNBC; optimal integration of sacituzumab govitecan into clinical practice
• Other antibody-drug conjugates under investigation for mTNBC (eg, ladiratuzumab vedotin, datopotamab deruxtecan)
• Available data with and ongoing investigation of other promising novel agents and strategies (eg, lenvatinib/pembrolizumab) for patients with advanced TNBC

Thank you for your interest in our CME program taking place in Chicago, IL. At this time ONLINE "IN-PERSON" PREREGISTERATION is closed for this event. SEATS ARE STILL AVAILABLE FOR THE PROGRAM AND WILL BE OFFERED - ON A FIRST COME FIRST SERVCE BASIS. Our Onsite Registration Desk will be open at 6:30 PM Central Time on Monday, June 6. If you are interested in attending, please visit our registration desk located outside the Grand Ballroom (Level 2) of the Hilton Chicago hotel (702 South Michigan Avenue). ASCO offers complimentary shuttle service from the McCormick Place Convention Center to this hotel. Information on shuttle service is available on the 2022 ASCO Annual Meeting website.

If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153.

Please note, onsite registration does not guarantee meal service which will be based on availability.